The measurement of CK18 fragment is recognized as a NASH biomarker and has been applied to several clinical trials in an effort to judge the effectiveness of new NASH medications22–24, but the existing ELISA has not been applied clinically due to variability of disease-related cut off values13,14. This evidence concerns the gene KRT18 and metabolic dysfunction-associated steatohepatitis.